Edit |   |
---|---|
Antigenic Specificity | PCSK9 (Tafolecimab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG2 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Tafolecimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PCSK9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. GPRC5D/CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is generically named tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of the anti-CD3 antibody is introduced into F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were also introduced into the IgG4 constant region. |
Immunogen | n/a |
Other Names | Tafolecimab, PCSK9 |
Gene, Accession # | n/a |
Catalog # | abx831565 |
Price | please inquire |
Order / More Info | PCSK9 (Tafolecimab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950